BRIEF-Seres Therapeutics CEO reports acquisition of 160,965 shares of co by exercise of options - SEC filing

* Seres Therapeutics CEO Roger Pomerantz reports acquisition

of 160,965 shares of co by exercise of options on May 18, at

price of $0.71 - SEC filing

Source text (http://bit.ly/1NAOQhm)

Further company coverage:

Read more